Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer

Alessia Di Legge; In Trivellizzi; Mc Moruzzi; Alessandra Pesce; Giovanni Scambia; Domenica Lorusso

doi:10.1097/IGC.0b013e31822d754e

Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer

Alessia Di Legge, In Trivellizzi, Mc Moruzzi, Alessandra Pesce, Giovanni Scambia, Domenica Lorusso

Risultato della ricerca: Contributo in rivista › Articolo in rivista

20 Citazioni (Scopus)

Abstract

Advanced or recurrent endometrial cancer is associated with a poor prognosis, and results obtained with systemic therapy are far from being impressive. Myocet is an interesting formulation of citrate conjugated doxorubicin encapsulated in nonpegylated liposomes. This phase 2 study was designed to evaluate the objective response rate and the toxicity profile of Myocet in women with advanced or recurrent endometrial cancer.

Lingua originale	English
pagine (da-a)	1446-1451
Numero di pagine	6
Rivista	International Journal of Gynecological Cancer
Volume	21
DOI	https://doi.org/10.1097/IGC.0b013e31822d754e
Stato di pubblicazione	Pubblicato - 2011

Keywords

Aged
Aged, 80 and over
Antibiotics, Antineoplastic
Carcinoma
Doxorubicin
Endometrial Neoplasms
Female
Humans
Middle Aged
Neoplasm Recurrence, Local
Treatment Failure

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1097/IGC.0b013e31822d754e

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{a403b6e1c56643298c821146bf21ad87,

title = "Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer",

abstract = "Advanced or recurrent endometrial cancer is associated with a poor prognosis, and results obtained with systemic therapy are far from being impressive. Myocet is an interesting formulation of citrate conjugated doxorubicin encapsulated in nonpegylated liposomes. This phase 2 study was designed to evaluate the objective response rate and the toxicity profile of Myocet in women with advanced or recurrent endometrial cancer.",

keywords = "Aged, Aged, 80 and over, Antibiotics, Antineoplastic, Carcinoma, Doxorubicin, Endometrial Neoplasms, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Treatment Failure, Aged, Aged, 80 and over, Antibiotics, Antineoplastic, Carcinoma, Doxorubicin, Endometrial Neoplasms, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Treatment Failure",

author = "{Di Legge}, Alessia and In Trivellizzi and Mc Moruzzi and Alessandra Pesce and Giovanni Scambia and Domenica Lorusso",

year = "2011",

doi = "10.1097/IGC.0b013e31822d754e",

language = "English",

volume = "21",

pages = "1446--1451",

journal = "International Journal of Gynecological Cancer",

issn = "1048-891X",

publisher = "Blackwell Science Incorporated:350 Main Street, Sixth Floor:Malden, MA 02148:(888)661-5800, (781)388-8250, EMAIL: csjournals@blacksci.com, INTERNET: http://www.blackwell-science.com, Fax: (781)388-8232",

}

TY - JOUR

T1 - Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer

AU - Di Legge, Alessia

AU - Trivellizzi, In

AU - Moruzzi, Mc

AU - Pesce, Alessandra

AU - Scambia, Giovanni

AU - Lorusso, Domenica

PY - 2011

Y1 - 2011

N2 - Advanced or recurrent endometrial cancer is associated with a poor prognosis, and results obtained with systemic therapy are far from being impressive. Myocet is an interesting formulation of citrate conjugated doxorubicin encapsulated in nonpegylated liposomes. This phase 2 study was designed to evaluate the objective response rate and the toxicity profile of Myocet in women with advanced or recurrent endometrial cancer.

AB - Advanced or recurrent endometrial cancer is associated with a poor prognosis, and results obtained with systemic therapy are far from being impressive. Myocet is an interesting formulation of citrate conjugated doxorubicin encapsulated in nonpegylated liposomes. This phase 2 study was designed to evaluate the objective response rate and the toxicity profile of Myocet in women with advanced or recurrent endometrial cancer.

KW - Aged

KW - Aged, 80 and over

KW - Antibiotics, Antineoplastic

KW - Carcinoma

KW - Doxorubicin

KW - Endometrial Neoplasms

KW - Female

KW - Humans

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Treatment Failure

KW - Aged

KW - Aged, 80 and over

KW - Antibiotics, Antineoplastic

KW - Carcinoma

KW - Doxorubicin

KW - Endometrial Neoplasms

KW - Female

KW - Humans

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Treatment Failure

UR - http://hdl.handle.net/10807/3748

U2 - 10.1097/IGC.0b013e31822d754e

DO - 10.1097/IGC.0b013e31822d754e

M3 - Article

SN - 1048-891X

VL - 21

SP - 1446

EP - 1451

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

ER -

Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo